ReviewClinical, cosmetic and investigational dermatology2015
Management of pemphigus vulgaris: challenges and solutions.
Review in Clinical, cosmetic and investigational dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06285435 (Activation of Coagulation as an Indicator of a Pro-thrombotic State in Patients With Pemphigus), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Activation of Coagulation as an Indicator of a Pro-thrombotic State in Patients With Pemphigus: A Case-control Study
Who cites it
28 citing papers in PubMed, 98 citations in OpenAlex.
- Postsurgical pemphigus vulgaris following thyroidectomy: a case report and review of the literature.Wiener medizinische Wochenschrift (1946) · 2026Review
- Evidence-Based Practice for Comprehensive Management of Pemphigus Skin Lesions: An Evidence Synthesis Review.Journal of clinical medicine · 2026Review
- Navigating the Complexities of Pemphigus Vulgaris: A Comprehensive Iranian Study.Immunity, inflammation and disease · 2026Article
- Pemphigus Vulgaris With an Elevated Faecal Calprotectin Mimicking Inflammatory Bowel Disease: A Case Report.Cureus · 2026Article
- Thiopurine Methyltransferase Levels and Azathioprine Outcomes in Thai Patients with Cutaneous Autoimmune Diseases.Clinical, cosmetic and investigational dermatology · 2026Article
- Nuts about pemphigus? A cross-sectional investigation into the role of nuts intake in modulating disease severity.BMJ nutrition, prevention & health · 2026Article
- Patient-Reported Outcomes on Quality of Life in Older Adults with Oral Pemphigus.Healthcare (Basel, Switzerland) · 2025Article
- Pemphigus relapse: Mechanisms, risk factors, and agents associated with disease recurrence.The Journal of dermatology · 2024Review
- Review
- Beyond the Surface: A Clinical Insight Into a 60-Year-Old Male With Pemphigus vulgaris.Cureus · 2024Article
- Anal involvement in patient with pemphigus vulgaris: Case report.International journal of surgery case reports · 2024Article
- Addressing Challenges in Diagnosis, Differential Diagnosis, and Treatment of Pemphigus: A Case Series.Diagnostics (Basel, Switzerland) · 2023Article
- Review
- Article
- Article
- Article
- Immunotherapy for Pemphigus: Present and Future.Frontiers in medicine · 2022Review
- An Updated Review of Pemphigus Diseases.Medicina (Kaunas, Lithuania) · 2021Review
- Oral Pemphigus Vulgaris.Cureus · 2021Article
- Complementary Chinese Herbal Medicine Therapy Improves Survival in Patients With Pemphigus: A Retrospective Study From a Taiwan-Based Registry.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main objective in the treatment of pemphigus vulgaris is to control the disease, prevent relapses, and avoid adverse events associated with the prolonged use of steroids and immunosuppressive agents. Systemic corticosteroids remain the gold standard treatment for pemphigus vulgaris. Azathioprine and mycophenolate mofetil are the first line of steroid-sparing treatment. Rituximab is extremely effective in recalcitrant pemphigus, when other treatments fail to control the disease. The European Dermatology Forum recommends tapering prednisolone by 25% every 2 weeks after the consolidation phase, and a 5 mg reduction every 4 weeks when the dose is reduced to <20 mg. If the patient relapses, options include increasing steroids back to the previous dose, adding an immunosuppressant if using steroid monotherapy, or replacing a first-line immunosuppressant by another if already on combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.